Search

Search Results

• 

  Anticoagulation in obese patients: challenges and strategies

  Alice Lipari, Esmeralda Capristo, Antonietta Ferretti, Erica De Candia

  18-09-2025

  https://doi.org/10.4081/btvb.2025.174

  1928

  PDF: 296

  HTML: 258

  XML: 138
• 

  Bioequivalence of von Willebrand factor-containing concentrates: implications for the choice in patients with von Willebrand disease. A position paper from the Italian Association of Hemophilia Centers

  Ezio Zanon, Giancarlo Castaman, Augusto Bramante Federici, Maria Elisa Mancuso, Gianfranco Pasut, Alberto Tosetto, Angiola Rocino, Rita Carlotta Santoro

  26-01-2026

  https://doi.org/10.4081/btvb.2026.415

  1064

  PDF: 280

  HTML: 110
• 

  Pharmacokinetics of extended half-life albumin-fused factor IX and heterogeneous F9 variants in hemophilia B: a retrospective cohort study

  Barbara Lunghi, Massimo Morfini, Silvia Linari, Dario Balestra, Alessio Branchini, Lisa Pieri, Donata Belvini, Laura Banov, Cristina Santoro, Giancarlo Castaman, Francesco Bernardi

  02-03-2026

  https://doi.org/10.4081/btvb.2026.413

  300

  PDF: 98

  Supplementary: 64

• PO05 | Intensive FVIII replacement in haemophilia patients with hypertrophic synovium: a randomized study I.L. Calcaterra¹, E. Baldacci², R. Marino³, F. Valeri⁴, R.C. Santoro⁵, G. Pasta⁶, C. Martinoli⁷, M. Di Minno¹ | ¹Department of Clinical Medicine and Surgery, Federico II University, Naples; ²Haematology, University Hospital Policlinico Umberto I, Roma; ³Haemophilia Center and thrombosis, Policlinico, Bari; ⁴Regional Centre for Haemorrhagic and Thrombotic Diseases, AOU Città Della Salute e Della Scienza; Turin; ⁵Centre for Hemorrhagic and Thrombotic Disorders, Pugliese Ciaccio Hospital, Catanzaro; ⁶Fondazione IRCCS San Matteo Hospital, Pavia; ⁷Department of Health Science DISSAL, University of Genoa, Unit of Radiology and IRCCS San Martino Hospital, Genoa, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.267

  521

  PDF: 0
• 

  Direct oral anticoagulants: does one dose fit all? Why, when and how testing

  Armando Tripodi

  15-01-2026

  https://doi.org/10.4081/btvb.2026.418

  1225

  PDF: 247

• PO89 | Apixaban for secondary prevention of venous thromboembolism in hemodialysis patients: pharmacokinetic profile and safety outcomes S. Guglielmo¹, E. De Bon², L. Scarano¹, R. Fabris¹, E. Pierobon³, S. Barbar² | ¹Internal Medicine, Department of Medicine; ²Thrombotic and Hemorrhagic Disorders Unit, Department of Medicine; ³Nephrology and Dialysis Unit, Azienda ULSS 6 Euganea, Cittadella and Camposampiero, Padua, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.359

  653

  PDF: 0
• 

  PO27 | URINE QUALITATIVE ASSESSMENT OF DIRECT ORAL ANTICOAGULANTS IN ROUTINE CLINICAL PRACTICE F. Schieppati^1|2, P. Gomez-Rosas^1|3, C. Ambaglio¹, V. Brusegan¹, O.C. Cretu¹, E. Galimberti¹, F. Zunino¹, L. Barcella¹, J. Harenberg^4|5, A. Falanga^1|2, M. Marchetti^1|2 | ¹Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy; ²School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy; ³Maastricht University Medical Center, Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands; ⁴Ruprecht Karls University of Heidelberg, Heidelberg, Germany; ⁵DOASENSE GmbH, Heidelberg, Germany

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.522

  185

  PDF: 66

• PO18 | Does muscle mass matter? Appendicular lean mass as a determinant of anti-XA activity in elderly patientes B.M. Zanforlini¹, V. Bernardi¹, E. Campello², E.M. Bicego¹, C. Curreri¹, A. Vaticano¹, C. Sartori¹, L. Manfron¹, A. Perencin¹, P. Rollo¹, A. Baruffol¹, L. Ruoso¹, C. Simion², C. Bulato², P. Berto², P. Simioni², G. Sergi¹ | ¹Department of Medicine, Geriatrics Section, University of Padova; ²Haemorrhagic and Thrombotic Diseases Unit, Department of Medicine DIMED, Padova University Hospital, Padova, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.278

  527

  PDF: 0
• 

  OC10 | FROM DESIGN TO CLINICAL PHASE 3 IN ONCOLOGY: CD13-TARGETED TISSUE FACTOR AND TUMOR INFARCTION W.E. Berdel, C. Schwöppe, C. Brand, K. Hessling, A.F. Berdel, T. Kessler, G. Lenz, R.M. Mesters, C. Schliemann | Department of Medicine A, University Hospital, Muenster, Germany

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.493

  231

  PDF: 53